梅波利祖马布在患有严重酸性喘与/或没有鼻多症的患者中的有效性:现实生活研究
Francisco Javier Bravo-Gutiérrez1, Juan Carlos Miralles-López2, José Valverde-Molina3
1Pulmonology Department, University General Hospital Santa Lucía, Cartagena (Murcia), Spain.
International archives of allergy and immunology
|November 30, 2023
概括
梅波利祖马布显著降低了严重的酸性喘 (SEA) 中的恶化和口服皮质类固醇的使用. 鼻息肉患者对这种有效治疗的反应率更高.
科学领域:
- 肺部病理学 肺部病理学
- 临床药理学 临床药理学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 严重的喘影响全球数以百万计的人,严重的疹性喘 (SEA) 代表了一个重要的亚组.
- 梅波利祖马布是SEA的既定治疗方法,改善了关键的临床结果.
- 了解治疗反应的变化,特别是有关鼻等并发病的变化,对于个性化医学至关重要.
研究的目的:
- 为了评估mepolizumab在SEA患者中的实际有效性.
- 评估恶化的变化,口服皮质类固醇 (OCS) 的使用,喘控制,生活质量和肺功能.
- 为了比较mepolizumab对SEA患者的反应,有和没有鼻多重症.
主要方法:
- 对SEA患者进行了回顾性多中心研究 (RE-ASGRAMUR),这些患者接受了至少一年的梅波利祖马布治疗.
- 分析临床数据,包括恶化,OCS摄入量,喘控制测试 (ACT),喘患者的微型生活质量 (miniAQLQ) 和1秒强制呼吸量 (FEV1).
- 具有和没有鼻的患者之间的治疗结果的比较.
主要成果:
- 梅波利祖马布治疗导致恶化严重减少 (中位数减少77.4%) 和OCS使用 (中位数减少56%).
- 在喘控制 (ACT),生活质量 (miniAQLQ) 和肺功能 (FEV1) 中观察到显著改善.
- 近50%的患者是超级响应者,超过24%的患者实现了完全响应;鼻息肉患者的超级响应者和完全响应率更高.
结论:
- 梅波利祖马布是SEA的安全有效疗法,可以证明改善了恶化,OCS依赖,喘控制,生活质量和肺功能.
- 鼻多重症的存在与具有统计学意义的超级响应者和完全响应者对梅波利祖马布的比例较高有关.
- 这些发现支持mepolizumab在SEA中的使用,在并发性鼻多重症患者中可能有更大的益处.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
305
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
305
01:19Antiasthma Drugs: Leukotriene Modifiers
320
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
320
01:24Antiasthma Drugs: Methylxanthines
238
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
238
01:26COPD: Management Using Bronchodilators and Corticosteroids
214
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
214
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
270
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
270
01:17Drugs Used in Lower Respiratory Disorders: Overview
451
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
451